Certara (NASDAQ:CERT) Price Target Cut to $15.00 by Analysts at UBS Group

Key Points

• UBS Group has reduced its price target for Certara's stock from $17.50 to $15.00, while maintaining a "buy" rating, indicating a potential upside of 34.29% from the stock's previous close.
• Certara's quarterly earnings showed a report of $0.07 EPS, missing the consensus estimate of $0.10, despite a year-over-year revenue increase of 12.1%.
• The stock currently has a consensus rating of "Moderate Buy" and a target price of $15.14, with several analysts providing varied ratings from "neutral" to "overweight".

Certara (NASDAQ:CERT - Get Free Report) had its price target cut by analysts at UBS Group from $17.50 to $15.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. UBS Group's price objective would suggest a potential upside of 43.27% from the company's previous close.

A number of other equities research analysts also recently issued reports on CERT. KeyCorp lowered their price target on shares of Certara from $18.00 to $15.00 and set an "overweight" rating on the stock in a report on Monday, July 14th. Robert W. Baird lifted their price target on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $11.00 to $14.00 in a report on Thursday, May 8th. JMP Securities reissued a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Finally, Morgan Stanley assumed coverage on Certara in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $16.00 price target for the company. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Certara has a consensus rating of "Moderate Buy" and a consensus price target of $15.14.

Certara Trading Down 4.3%

NASDAQ:CERT traded down $0.47 during mid-day trading on Thursday, hitting $10.47. 1,920,474 shares of the company's stock were exchanged, compared to its average volume of 1,723,568. The company has a 50 day simple moving average of $10.92 and a 200-day simple moving average of $11.73. The company has a current ratio of 2.16, a quick ratio of 2.16 and a debt-to-equity ratio of 0.27. Certara has a fifty-two week low of $8.64 and a fifty-two week high of $15.69. The firm has a market capitalization of $1.68 billion, a P/E ratio of 209.44 and a beta of 1.42.

Certara (NASDAQ:CERT - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). The company had revenue of $104.57 million for the quarter, compared to analyst estimates of $104.14 million. Certara had a net margin of 1.97% and a return on equity of 5.11%. The firm's revenue was up 12.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.07 EPS. As a group, research analysts expect that Certara will post 0.28 earnings per share for the current year.

Institutional Trading of Certara

A number of institutional investors have recently bought and sold shares of the company. ArrowMark Colorado Holdings LLC boosted its holdings in Certara by 164.2% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock valued at $66,171,000 after purchasing an additional 3,861,674 shares in the last quarter. Geneva Capital Management LLC boosted its stake in Certara by 7.8% in the 2nd quarter. Geneva Capital Management LLC now owns 6,114,895 shares of the company's stock worth $71,544,000 after purchasing an additional 443,206 shares during the period. Teacher Retirement System of Texas grew its holdings in shares of Certara by 25.3% in the 2nd quarter. Teacher Retirement System of Texas now owns 5,674,485 shares of the company's stock valued at $66,391,000 after acquiring an additional 1,145,554 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Certara by 13.6% in the 1st quarter. Ameriprise Financial Inc. now owns 4,295,566 shares of the company's stock valued at $42,526,000 after purchasing an additional 515,911 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its stake in Certara by 7.0% in the 1st quarter. Mackenzie Financial Corp now owns 1,793,327 shares of the company's stock valued at $17,754,000 after purchasing an additional 117,089 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.